Novanta Inc. (NOVT) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 27, 2025. Novanta Inc. is a global supplier of core technology solutions for medical and advanced industrial original equipment manufacturers (OEMs). The company operates under two reportable segments: Automation Enabling Technologies and Medical Solutions. A significant event during the period was the acquisition of Keonn Technologies, S.L., an RFID solutions manufacturer, on April 8, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $241.0 million | $235.9 million | $474.4 million | $466.8 million |
| Gross Profit | $106.7 million | $103.7 million | $211.1 million | $204.1 million |
| Gross Margin | 44.3% | 44.0% | 44.5% | 43.7% |
| Operating Income | $14.9 million | $25.7 million | $47.3 million | $51.3 million |
| Net Income | $4.5 million | $13.8 million | $25.7 million | $28.4 million |
| Diluted EPS | $0.12 | $0.38 | $0.71 | $0.79 |
| Cash & Equivalents | $109.9 million (as of June 27, 2025) | |||
| Total Debt | $459.2 million (as of June 27, 2025) | |||
| Operating Cash Flow (YTD) | $46.8 million | $73.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Q2 revenue increased 2.2% year-over-year, driven by the Keonn acquisition (+$5.3M) and growth in the Automation Enabling Technologies segment. YTD revenue grew 1.6%.
- Profitability Decline: Operating income decreased 42.0% in Q2 and 7.8% YTD. This was primarily due to a significant increase in restructuring, acquisition, and related costs ($12.6M in Q2 vs. $2.5M in Q2 2024).
- Restructuring Costs: The company initiated a 2025 restructuring program in Q2, recording $6.8M in charges. Total expected costs for this program range from $20.0M to $25.0M.
- Foreign Exchange: The company recorded a net foreign exchange transaction loss of $2.7M in Q2 (vs. $0.3M loss in Q2 2024), impacting net income.
- Debt Refinancing: On June 27, 2025, the company entered into a new $1.0 billion credit facility (Fourth Amended and Restated Credit Agreement), replacing the prior agreement. The weighted average interest rate decreased to 5.35% in Q2 2025 from 6.74% in Q2 2024.
Guidance, Outlook, and Risks
- Restructuring Outlook: The 2025 restructuring program is expected to be substantially completed by the end of 2026. The 2024 restructuring program is expected to be completed by the end of 2025 with an additional $1.5M to $2.5M in charges.
- Capital Expenditures: The company expects to spend approximately $15M to $20M in 2025 on capital expenditures.
- Acquisition Integration: Keonn Technologies is included in the Medical Solutions segment. The acquisition included up to €20.0 million ($21.9 million) in contingent consideration based on revenue targets through 2027.
- Tax Legislation: The company is assessing the impact of the U.S. "One Big Beautiful Bill Act" (H.R.1) enacted on July 4, 2025, which includes modifications to the international tax framework.
- Risks: Key risks include macroeconomic conditions, geopolitical tensions, trade policy changes (tariffs), supply chain disruptions, and the ability to successfully integrate acquisitions.
Investor Verification Checklist
- Restructuring Execution: Verify the progress and cost containment of the 2025 and 2024 restructuring programs against the stated ranges ($20-25M and $1.5-2.5M respectively).
- Keonn Performance: Monitor Keonn Technologies' revenue contribution and ability to meet the targets required for the $21.9M contingent consideration.
- ERP Implementation: Assess the impact of the Enterprise Resource Planning (ERP) system implementation costs on SG&A expenses, which drove a portion of the operating expense increase.
- Debt Covenants: Confirm continued compliance with the new credit agreement covenants, specifically the maximum consolidated leverage ratio (currently 1.93 vs. 3.50 limit).
- Foreign Exchange Exposure: Review hedging strategies given the significant foreign exchange transaction losses recorded in the current period.